Search

Your search keyword '"Cécile Brunet-Cartier"' showing total 3 results
Start Over Author "Cécile Brunet-Cartier" Topic gestation
3 results on '"Cécile Brunet-Cartier"'

1. Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?

Author

Jérôme Le Chenadec, Anrs Epf Co, Pierre Frange, Ana Canestri, Roland Tubiana, Laurent Mandelbrot, Josiane Warszawski, Cécile Brunet-Cartier, Laurent Cotte, Jeanne Sibiude, Jacques Reynes, Cédric Arvieux, and Centre for Reproductive Medicine - Gynaecology

Subjects
0301 basic medicine, Microbiology (medical), safety, medicine.medical_specialty, RFC, Anti-HIV Agents, HIV Infections, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pregnancy, Obstetrics and Gynaecology, medicine, Emtricitabine, Humans, Pharmacology (medical), 030212 general & internal medicine, Pharmacology, business.industry, Obstetrics, Rilpivirine, Infant, Newborn, Gestational age, Viral Load, medicine.disease, 030112 virology, 3. Good health, HIV-1-positive, Regimen, Infectious Diseases, chemistry, Cohort, HIV-1, Gestation, Ritonavir, Female, women, business, Viral load, medicine.drug
Abstract

BackgroundSafety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy.ObjectivesTo describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC.MethodsIn the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010–18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (ResultsAmong 247 women included, 88.7% had viral suppression at the beginning of pregnancy. Overall, 184 women (74.5%) switched to an RFC (mostly PI/ritonavir-based regimens) at a median gestational age of 8.0 WG. Plasma HIV-1 RNA nearest delivery was ConclusionsIn virologically suppressed women initiating pregnancy, continuing rilpivirine was associated with better virological outcome than changing regimen. We did not observe a higher risk of adverse pregnancy outcomes.

Published
2019

2. Does changing antiretroviral therapy in the first trimester for pregnancy-related concerns have an impact on viral suppression ?: Changing ART in pregnancy and viral suppression ?

Author

Josiane Warszawski, Agnès Bourgeois-Moine, Caroline Simon Toulza, Albert Faye, Violaine Peyronnet, Laurent Mandelbrot, Eida Bui, Jérôme Le Chenadec, Jeanne Sibiude, Cécile Brunet-Cartier, Olivia Dialla, Véronique Avettand-Fenoel, Roland Tubiana, Delphine Peretti, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Département d'obstétrique et de gynécologie [AP-HP Hôpital Louis-Mourier] (DHU Risks in Pregnancy), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris-Sud [Le Kremlin-Bicêtre] (Faculté de Médecine), Université Paris Diderot - Paris 7 (UPD7), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Nantes (CHU Nantes), Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), Université Paris Descartes - Paris 5 (UPD5), CHU Necker - Enfants Malades [AP-HP], AP-HP Hôpital universitaire Robert-Debré [Paris], Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), This work was supported by the French Agence Nationale de Recherche sur le SIDA (ANRS)., and ANRS EPF-French Perinatal Cohort Study

Subjects
Adult, viral suppression, medicine.medical_specialty, Anti-HIV Agents, antiretroviral therapy, HIV Infections, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Pregnancy, Medicine, Humans, Pharmacology (medical), guidelines, 030212 general & internal medicine, Prospective Studies, Young adult, Pregnancy Complications, Infectious, Prospective cohort study, Propensity Score, Survival analysis, preconception care, 0303 health sciences, 030306 microbiology, business.industry, Obstetrics, Drug Substitution, Pregnancy Outcome, HIV, Viral Load, medicine.disease, [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], Survival Analysis, Infectious Disease Transmission, Vertical, 3. Good health, treatment switch, Pregnancy Trimester, First, Infectious Diseases, Logistic Models, Cohort, Propensity score matching, HIV-1, Gestation, Female, business, Viral load
Abstract

International audience; OBJECTIVE:To determine whether changing antiretroviral therapy (ART) during pregnancy because of concern about fetal risks led to poorer virological outcomes.METHODS:All pregnancies in women with HIV-1 infection enrolled in the national multicenter prospective French Perinatal cohort at 14 week gestation or more were included between January 2005 and December 2015, if the mother was on ART at conception with a plasma viral load

Published
2019
Full Text
View/download PDF

3. Does Changing Antiretroviral Therapy in the First Trimester for Pregnancy-Related Concerns Have an Impact on Viral Suppression?

Author

Olivia Dialla, Violaine Peyronnet, Josiane Warszawski, Laurent Mandelbrot, Delphine Peretti, Jérôme Le Chenadec, Caroline Simon Toulza, Eida Bui, Cécile Brunet-Cartier, Roland Tubiana, Véronique Avettand-Fenoel, Albert Faye, Jeanne Sibiude, and Agnès Bourgeois Moine

Subjects
Pregnancy, medicine.medical_specialty, biology, Obstetrics, business.industry, medicine.disease, biology.organism_classification, Informed consent, Propensity score matching, Cohort, medicine, Gestation, Sida, business, Viral load, Survival analysis
Abstract

Objective: To determine whether changing antiretroviral therapy (ART) during pregnancy in order to follow guidelines because of concern about fetal risks led to poorer virological outcomes. Methods: All pregnancies in women with HIV1 infection enrolled in the national multicenter prospective French Perinatal cohort were included between 01/2005 and 12/2015, at 14 gestational weeks or more and if the mother was on ART at conception with a plasma viral load < 50 copies/ml. The reasons for a change in the ART were analyzed according to treatment guidelines at the time of the pregnancy, and defined as for pregnancy-related concerns in the absence of reported maternal intolerance. Virological and pregnancy outcomes were studied by survival analysis and logistic regression adjusted for a propensity score established for each patient according to baseline characteristics. Results: Of 10553 pregnancies in the cohort, 1797 were taking ART at conception and had a viral load

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results